JP2013509392A5 - - Google Patents

Download PDF

Info

Publication number
JP2013509392A5
JP2013509392A5 JP2012535977A JP2012535977A JP2013509392A5 JP 2013509392 A5 JP2013509392 A5 JP 2013509392A5 JP 2012535977 A JP2012535977 A JP 2012535977A JP 2012535977 A JP2012535977 A JP 2012535977A JP 2013509392 A5 JP2013509392 A5 JP 2013509392A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
hydrogen
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012535977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509392A (ja
JP5784620B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/054749 external-priority patent/WO2011051858A1/en
Publication of JP2013509392A publication Critical patent/JP2013509392A/ja
Publication of JP2013509392A5 publication Critical patent/JP2013509392A5/ja
Application granted granted Critical
Publication of JP5784620B2 publication Critical patent/JP5784620B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012535977A 2009-10-28 2010-10-20 カゼインキナーゼ阻害剤としてのイミダゾール誘導体 Active JP5784620B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25550609P 2009-10-28 2009-10-28
US61/255,506 2009-10-28
PCT/IB2010/054749 WO2011051858A1 (en) 2009-10-28 2010-10-20 Imidazole derivatives as casein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2013509392A JP2013509392A (ja) 2013-03-14
JP2013509392A5 true JP2013509392A5 (enExample) 2013-11-28
JP5784620B2 JP5784620B2 (ja) 2015-09-24

Family

ID=43301770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535977A Active JP5784620B2 (ja) 2009-10-28 2010-10-20 カゼインキナーゼ阻害剤としてのイミダゾール誘導体

Country Status (22)

Country Link
US (1) US8518944B2 (enExample)
EP (1) EP2493876B1 (enExample)
JP (1) JP5784620B2 (enExample)
KR (1) KR101421852B1 (enExample)
CN (1) CN102686580B (enExample)
AR (1) AR078797A1 (enExample)
AU (1) AU2010311035B2 (enExample)
CA (1) CA2777632C (enExample)
DK (1) DK2493876T3 (enExample)
ES (1) ES2460065T3 (enExample)
HR (1) HRP20140252T1 (enExample)
IL (1) IL219190A0 (enExample)
IN (1) IN2012DN03182A (enExample)
MX (1) MX2012004997A (enExample)
PL (1) PL2493876T3 (enExample)
PT (1) PT2493876E (enExample)
RS (1) RS53246B (enExample)
SI (1) SI2493876T1 (enExample)
TW (1) TW201125864A (enExample)
UY (1) UY32977A (enExample)
WO (1) WO2011051858A1 (enExample)
ZA (1) ZA201202776B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
EP3181133B1 (en) 2010-12-20 2019-07-24 Pfizer Inc Novel fused pyridine compounds as casein kinase inhibitors
EP2892506B1 (en) 2012-09-07 2021-11-03 Massachusetts Eye & Ear Infirmary Treating hearing loss with the gamma-secretase inhibitor ly411575
JP6267231B2 (ja) 2012-12-21 2018-01-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カゼインキナーゼ1δ/ε阻害剤としての新規な置換イミダゾール
US9732065B2 (en) 2013-05-30 2017-08-15 Sumitomo Dainippon Pharma Co., Ltd. Cyclic aminomethyl pyrimidine derivative
SG11201606427SA (en) 2014-02-07 2016-09-29 Agency Science Tech & Res 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
WO2016149756A1 (en) 2015-03-23 2016-09-29 The University Of Melbourne Treatment of respiratory diseases
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
AU2018262108A1 (en) * 2017-05-03 2019-11-21 The University Of Melbourne Compounds for the treatment of respiratory diseases
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
AU2019336540B2 (en) * 2018-09-09 2025-02-13 Qanatpharma Ag Use of casein kinase 1 inhibitors for treating vascular diseases
AU2019374731B2 (en) * 2018-11-07 2025-08-21 Tianli Biotech Pty Ltd Compounds and compositions for the treatment of respiratory diseases
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
CN115335057A (zh) * 2020-03-27 2022-11-11 北京原基华毅生物科技有限公司 抑制酪蛋白激酶的方法
EP4126878A4 (en) * 2020-03-27 2024-07-10 Gritscience Biopharmaceuticals Co., Ltd. COMPOUNDS AS CASEIN KINASE INHIBITORS
AR122711A1 (es) * 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012154A1 (en) * 1990-12-31 1992-07-23 Fujisawa Pharmaceutical Co., Ltd. Imidazotriazine derivatives
IL110296A (en) 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
WO1997035856A1 (en) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
JP2004536597A (ja) * 2001-06-18 2004-12-09 ザ ロックフェラー ユニバーシティー 代謝共役型グルタミン酸受容体シグナル伝達経路を介する神経機能の調節
CN100439367C (zh) * 2003-12-11 2008-12-03 安万特药物公司 作为酪蛋白激酶Iε抑制剂的取代的1H-吡咯并[3,2-b、3,2-c和2,3-c]吡啶-2-甲酰胺以及相关类似物
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
ES2334927T3 (es) * 2004-08-19 2010-03-17 Aventis Pharmaceuticals Inc. Derivados de 3-ariltioindol-2-carboxamida y sus analogos como imhibidores de caseina quinasa i.
CA2626789A1 (en) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
EP3181133B1 (en) * 2010-12-20 2019-07-24 Pfizer Inc Novel fused pyridine compounds as casein kinase inhibitors

Similar Documents

Publication Publication Date Title
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2017502940A5 (enExample)
JP2018524390A5 (enExample)
EA201391209A1 (ru) Мостиковые производные пиперидина
JP2016540742A5 (enExample)
AR062937A1 (es) Compuestos que modulan el receptor cb2
WO2009082268A3 (ru) ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
AR066043A1 (es) Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1)
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
JP2012511588A5 (enExample)
JP2013533253A5 (enExample)
JP2015501833A5 (enExample)
MX2015017343A (es) Derivados de pirrolopiridina o pirazolopiridina.
JP2016503797A5 (enExample)
EA201391341A1 (ru) Производные гетероциклических аминов
AR043501A1 (es) Derivados de imidazol-4-il-etinil-piridina
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
JP2020527175A5 (enExample)
JP2012097115A5 (enExample)
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
EA200400305A1 (ru) 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность
JP2008513485A5 (enExample)
JP2006523698A5 (enExample)
JP2016500653A5 (enExample)